New blood test could spot hidden cancer cells that spread

NCT ID NCT05346536

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study compares two blood test methods for detecting circulating tumor cells (CTCs) that express a protein called Axl, which is linked to more aggressive cancer. The new technique, called EPIDROP, is being tested against the standard CellSearch method in patients with metastatic pancreatic or breast cancer. If the EPIDROP test works well, it could provide a simpler way to track cancer spread and response to treatment without needing a tissue biopsy.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

What this could lead to
If the EPIDROP test proves accurate, it could offer a simpler, non-invasive way to monitor cancer progression and guide treatment decisions.
What could go wrong
This is a small, early-stage study focused on comparing two lab techniques, not on treating the disease. The new test may not be more accurate or practical than the existing method.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIRCULATING TUMOR CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU Montpellier

    RECRUITING

    Montpellier, 34090, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.